Conway, B., Tebas, P., Slama, L. Understanding the clinical implications of low-level viremia in ART-treated individuals , AIDS, 39(11): 2025,1656-1657

Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., Li, J. Z., MacBrayne, C., Nakamura, M. M., Riley, L., Shafer, R. W., Shoham, S., Tebas, P., Tien, P. C., Loveless, J., Falck-Ytter, Y., Morgan, R. L., Gandhi, R. T. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept , Clin Infect Dis: 2025

Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., Li, J. Z., MacBrayne, C., Nakamura, M. M., Riley, L., Shafer, R. W., Shoham, S., Tebas, P., Tien, P. C., Loveless, J., Falck-Ytter, Y., Morgan, R. L., Gandhi, R. T. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab , Clin Infect Dis: 2025

Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., Li, J. Z., MacBrayne, C., Nakamura, M. M., Riley, L., Shafer, R. W., Shoham, S., Tebas, P., Tien, P. C., Loveless, J., Falck-Ytter, Y., Morgan, R. L., Gandhi, R. T. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab , Clin Infect Dis: 2025

Bhimraj, A., Falck-Ytter, Y., Baden, L. R., Bedimo, R., Cawcutt, K., Cheng, V. C., Chew, K. W., Chiotos, K., Daar, E. S., Dzierba, A. L., Glidden, D. V., Hardy, E. J., Johnson, S., Kim, A. Y., Li, J. Z., MacBrayne, C., Martin, G. S., Nadig, N., Nakamura, M. M., Pearson, J. C., Riley, L., Shafer, R. W., Shoham, S., Shumaker, A. H., Tebas, P., Tien, P. C., Loveless, J., Morgan, R. L., Gandhi, R. T. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness , Clin Infect Dis: 2025

Wei, Y., Ma, H. K., Wong, M. E., Back, H., Papasavvas, E., Mounzer, K., Aberra, F., Morgenstern, R., Tebas, P., Konnikova, L., Montaner, L. J., Ho, Y. C. Transcription factor BACH2 shapes tissue-resident memory T cell programs to promote HIV-1 persistence , Immunity: 2025

Taiwo, B. O., Zheng, Y., Rodriguez, K., Burke, L., Reeves, J. D., Scarsi, K. K., Gama, L., Petropoulos, C. J., Belaunzaran-Zamudio, P. F., Wannamaker, P., D'Amico, R., Rathod, P., Bar, K., Tebas, P. Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults with HIV-1: ACTG A5357 , Clin Infect Dis: 2025

McMyn, N. F., Varriale, J., Wu, H. W. S., Hariharan, V., Moskovljevic, M., Tan, T. S., Lai, J., Singhal, A., Lynn, K., Mounzer, K., Tebas, P., Montaner, L. J., Hoh, R., Yu, X. G., Lichterfeld, M., Simonetti, F. R., Kovacs, C., Deeks, S. G., Siliciano, J. M., Siliciano, R. F. Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies , J Clin Invest: 2025

Tebas, P. Future of bNAbs in HIV Treatment , Curr HIV/AIDS Rep, 22(1): 2025,34

Jadlowsky, J. K., Hexner, E. O., Marshall, A., Grupp, S. A., Frey, N. V., Riley, J. L., Veloso, E., McConville, H., Rogal, W., Czuczman, C., Hwang, W. T., Li, Y., Leskowitz, R. M., Farrelly, O., Karar, J., Christensen, S., Barber-Rotenberg, J., Gaymon, A., Aronson, N., Bernstein, W., Melenhorst, J. J., Roche, A. M., Everett, J. K., Zolnoski, S. A., McFarland, A. G., Reddy, S., Petrichenko, A., Cook, E. J., Lee, C., Gonzalez, V. E., Alexander, K., Kulikovskaya, I., Ramirez-Fernandez, A., Minehart, J. C., Ruella, M., Gill, S. I., Schuster, S. J., Cohen, A. D., Garfall, A. L., Shah, P. D., Porter, D. L., Maude, S. L., Levine, B. L., Siegel, D. L., Chew, A., McKenna, S., Lledo, L., Davis, M. M., Plesa, G., Herbst, F., Stadtmauer, E. A., Tebas, P., DiNofia, A., Haas, A., Haas, N. B., Myers, R., O'Rourke, D. M., Svoboda, J., Tanyi, J. L., Aplenc, R., Jacobson, J. M., Ko, A. H., Cohen, R. B., June, C. H., Bushman, F. D., Fraietta, J. A. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies , Nat Med, 31(4): 2025,1134-1144